Background: The aim of our study was to determine whether the presence of bone metastases affects outcomes in patients with metastatic clear-cell renal cell carcinoma (m-ccRCC) receiving sunitinib.
introduction
Renal cell carcinoma (RCC) accounts for about 2% of all cancers worldwide [1] . Although the majority of patients will be cured by nephrectomy alone, up to one-third of patients present with metastatic renal cell carcinoma (m-RCC) [2] [3] [4] . New therapies targeting the vascular endothelial growth factor (VEGF) pathway (e.g. sunitinib, sorafenib, and bevacizumab) [5, 6] or the mammalian target of rapamycin (mTOR) pathway (e.g. everolimus and temsirolimus) have recently superseded cytokines as first-line treatment of advanced or metastatic RCC.
As a consequence, the predictive and prognostic factors that were developed for patients on cytokine therapy, and that are used to design trials, counsel patients and select therapy, need to be reviewed. The Memorial Sloan-Kettering Cancer Center (MSKCC) criteria stratify patients receiving immunotherapy into three risk groups (favorable, intermediate, and poor prognoses) according to five factors adversely associated with overall survival (OS): time from initial diagnosis to start of systemic therapy (<1 year), elevated baseline lactate dehydrogenase (LDH), corrected calcium, low baseline hemoglobin, and low Karnofsky performance status [7, 8] . These criteria were validated by the Cleveland Clinic that added two further criteria with negative prognostic value: prior radiotherapy and more than one site of metastasis [9] .
Three published studies have investigated prognostic factors in patients receiving targeted inhibitors: (i) In the pivotal trial on sunitinib in 375 patients, corrected calcium, number of metastatic sites (one or more than one), presence of liver metastases, thrombocytosis, LDH level, and <1 year from diagnosis to treatment were significantly associated with progression-free survival (PFS) [10] ; (ii) In a study of a variety of targeted agents including sunitinib in 120 patients, five adverse prognostic factors for PFS were identified: <2 years from diagnosis to current treatment, elevated baseline platelet and neutrophil counts, abnormal baseline corrected serum calcium, and initial Eastern Cooperative Oncology Group (ECOG) performance status (PS) >0 [11] . (iii) In the most recent study of three targeted drugs including sunitinib on 643 patients, four of the five MSKCC criteria for OS were independent predictors of short survival (baseline hemoglobin and corrected calcium, PS, and <1 year from diagnosis to treatment), as well as two other factors: elevated baseline neutrophil and platelet counts [12] . There is rising interest in the impact of bone metastases on outcome in RCC [13] . The objective of our study was to investigate if the presence of bone metastases has a negative impact on PFS and OS in patients receiving sunitinib. Data were collated on patient age at diagnosis, gender, prior treatment, Fuhrman grade, ECOG PS at initiation of sunitinib therapy, number and sites of metastases (bone, liver, lung, and lymph nodes), bone-targeted therapy, baseline platelet count (>400 000/mm 3 ), neutrophil count (>4500/ mm 3 ), LDH level (>1.5· upper limit of normal), corrected serum calcium (<8.5 or >10 mg/dl) and time between nephrectomy and diagnosis of metachronic metastases. Metastases diagnosed within 3 months of nephrectomy were considered synchronic. All patients underwent thoracic and abdominal computed tomography (CT) scan every 2-3 months. Bone metastases were detected by CT scan and/or bone scintigraphy. Bone scintigraphy was a standard investigation before inclusion and-in presence of bone metastases-during treatment in some international trials or was carried out if bone-related symptoms were present at inclusion or if they occurred during treatment.
The primary end point of our study was PFS and OS. Secondary end point was response rate (RR). Results are reported as medians with 95% confidence intervals (CIs). The cutoff date was 31 January 2010. An objective response was defined according to RECIST. According to RECIST 1.0., the target lesions were not the bone metastases but the metastases in other organs. In patients with only bone metastases (eight in our series), only complete response, stable disease, and progressive disease were noted not partial response. Patients who did not reach the first CT scan evaluation were excluded. PFS and OS distributions were estimated using the KaplanMeier product-limit method. Potential prognostic variables were analyzed by univariate analysis by the Maentel Hetzel test on the pooled data from all four centers. Those with a P-value <0.20 in the univariate analysis were entered into a multivariate analysis. The Cox proportionalhazards model with stepwise variable selection was used, with a P = 0.05 threshold for determining variable entry and removal from the model. For internal validation, data from the center with the largest number of patients (HEGP) were compared with the pooled data from the three other centers. All statistical analyses were conducted using GraphPad Prism 5 and StatView software. Table 1 . Median follow-up was 40 months. Mean age at diagnosis was similar in all groups. At the start of sunitinib treatment, 98% of the patients had undergone prior nephrectomy, 51% had received prior cytokine therapy (interferon-a, interleukin-2, or both), and approximately 20% had received prior chemotherapy. Seventy-six patients (34%) had bone metastases, 55 (25%) had metastases confined to the lung and/or retroperitoneal or mediastinal lymph nodes (denoted 'lung and/or LN'), and 53 (24%) had liver metastases. Compared with patients without bone metastases, patients with bone metastases had a higher incidence of M1 disease (51% versus 30%) and Fuhrman grade 4 tumors (24% versus 8%) at initial diagnosis and a higher incidence of PS >0 (ECOG) (53% versus 22%) and poor prognosis (MSKCC) (37% versus 9%) at the start of sunitinib therapy (all results are significant, see 95% CI in Table 1 ). They also had a higher mean number of metastatic sites. Of the 76 patients with bone metastases, 51 presented with 1-5 bone metastases, 10 with 6-10, and 5 with >10. Local bone-directed therapy (radiotherapy, cimentoplasty, resection, embolization, nailing, or a combination of these local therapies) was documented in the files of 50 patients and biphosphonate administration in the files of 26 patients.
The overall RR (Table 2) to sunitinib was 48%, median PFS 14.0 months, and median OS 28.7 months. By the time of analysis, 116/214 assessable patients (54%) had died.
Compared with patients without bone metastases, patients with bone metastases had a significantly shorter median PFS (8.2 versus 19.1 months; P < 0.0001) and median OS (19.5 versus 38.5 months, P < 0.0001) ( Figure 1, panel B) . By the time of analysis, 67/72 (93%) of assessable patients with bone metastases versus 97/145 (67%) without had developed disease progression and significantly more patients had died [77% (67-87) versus 42% (34-50)]. Early death due to skeletalrelated events such as myelocompression was encountered in one patient only. The RR was lower in patients with bone metastases than in those without [35% (24-46) versus 55% (47-63); hazard ratio (HR) = 0.64]. At progression, among assessable patients, second-line targeted therapy was initiated in 38/68 (56%) patients with bone metastases versus 72/101 (71%) patients without bone metastases. Estimated survival at 1, 2, 3, and 4 years was 64%, 39%, 21%, and 17%, respectively, in patients with bone metastases and 83%, 65%, 57%, and 42%, respectively, in those without bone metastases.
Concerning the site of progression, data were available in 59/76 patients with bone metastases and 91/147 patients without bone metastases. Among the 59 patients with bone metastases, 11 (19%) experienced progression of bone metastases only (2 of them only had bone metastases), 19 (32%) experienced progression of bone and other metastases, and 29 (49%) experienced progression at metastatic sites other than bone. Among the 91 patients without bone metastases who had reached progression at time of analysis, 8 (9%) developed bone metastases (3 also had disease progression at other sites) and 83 were progressive at other sites without developing bone metastasis.
Patients with liver metastases had an RR of 38% versus 51% in patients without liver metastases, a median PFS of 11.3 months (versus 16.1 months; P = 0.3), a mortality rate of 58% (versus 53%) and a median OS of 23.6 months (versus 30.7 months; P = 0.3). At the risk of unreliable results because of reduced patient numbers, we analyzed among the patients with liver metastases, the subgroup of patients with (n = 17) and without (n = 36) bone metastases. The results of the analysis are: a RR of 19% and 47%, a median PFS of 7.0 and 17.0 months (P = 0.0007) (Figure 1 , panels G and H), progression reached in 100% and 74%, a mortality rate of 88% and 42%, and a median OS of 11.5 and 38.7 months (P = 0.001), respectively.
The patients with metastatic spread confined to the 'lung and/or LN' had an RR of 59% (46-72) versus 44% (36-52) (HR = 1.34) for those with metastatic spread beyond 'lung and/ or LN', a median PFS of 21.2 (versus 11.9 months; P = 0.002) and a median OS of 40.0 (versus 23.6 months; P = 0.007). By the time of analysis, only 62% of patients had developed disease progression ( Figure 1 , panel I) and only 41% had died [41% (28-54) versus 59% (51-67)]. Second-line targeted therapy could be initiated in 28/37 (76%) patients. Estimated survival at 1, 2, 3, and 4 years was 84%, 74%, 62% and 38%, respectively.
On univariate analysis, the presence of bone metastases and the spread of metastases beyond the 'lung and/or LN' were significantly associated with PFS and OS (Table 3 ). Significant associations were also found with the following variables: platelet count, neutrophil count, PS (ECOG), and number of metastatic sites. Time from diagnosis to systemic treatment reached statistical significance for OS only and not for PFS. (Table 4) , the presence of bone metastasis was an independent factor linked to PFS. In the final model, it was the dominant factor (P < 0.0001) followed by elevated platelet count (P = 0.03). No other factor was independently associated with PFS, which is probably due to the limited number of patients in our multivariate analysis due to missing data. The presence of bone metastases was also the most powerful independent factor linked to OS (P = 0.001) followed by PS (P = 0.008). No other factor was independently associated with OS.
As an internal validation, we compared the HEGP population (n = 98) with the overall population from the three other centers (n = 125). These two populations had similar clinical features (Fuhrman grade, M-status, and PS) except that the percentage of patients with a poor prognosis (MSKCC) at the start of systemic therapy was lower in the HEGP population [7% (1-13) versus 21% (13-29)]. The RR, PFS, and OS data were highly similar for both populations (Figure 1, panels C-F) . Univariate analysis indicated that for the HEGP population, the presence of bone metastases was the most significant factor associated with PFS (P = 0.0002) and a highly significant factor associated with OS (P = 0.006), whereas for the combined three-center population, the presence of bone metastases was the most significant factor associated with both PFS (P < 0.0001) and OS (P = 0.0003).
discussion
In our series, m-RCC patients without bone metastases have a better outcome on treatment with sunitinib than patients with bone metastases: median PFS and OS are twice as long and upon disease progression on sunitinib, they were more likely candidates for second-line targeted therapy.
Our findings agree with those of a multivariate analysis on data of 375 patients receiving first-line sunitinib (abstract form only), in which the absence of bone metastases was also associated with longer OS (HR = 1.423, P = 0.0251) [14] . This finding might be an anti-VEGF class effect because in a series of 58 m-RCC patients treated first line with sorafenib, Riechelmann reports on multivariate analysis a shorter median PFS in case of bone metastases (4.7 versus 11.2 months; P = 0.02) [15] . Choueiri found in 120 m-RCC patients, treated with several targeted therapies, a median PFS of 10.7 (with bone metastases) versus 16.5 months (without) (P = 0.08) [11] .
In our series, the impact of liver metastases was not as important as the impact of bone metastases. Moreover, we observed, although these subgroups are small, that patients combining liver and bone metastases had a very poor prognosis, meanwhile the prognosis of those with liver but without bone metastases was not worse than the prognosis of the patients without bone metastases.
Patients with metastatic disease limited to lung metastases and retroperitoneal and mediastinal lymph node metastases were among the best responders to sunitinib. However, their RR, PFS, and OS are not significantly different from those patients with spread beyond 'lung and/or LN' but without bone metastases. Moreover, the factor 'lung and/or LN' metastases was not statistically significant in the multivariate analysis probably because it is dependent on the factor 'presence of bone metastases'.
At this moment, we are unable to explain why the presence of bone metastases seems to be an important adverse factor for outcome. Nevertheless, our data suggest some possible mechanisms. On one hand, our observations suggest that m-RCCs with bone metastases are an aggressive subtype of m-RCC. In the group of patients with bone metastases, 51% of the patients had metastases at the initial diagnosis of the kidney tumor and 49% developed metachronic metastases, whereas in the group without bone metastases, only 30% were initially metastatic. In patients with metachronic metastases, the median time between nephrectomy and diagnosis of metastases was shorter in patients presenting with than without bone metastases (22 versus 26.5 months). In patients with bone metastases, 24% of RCCs were Fuhrman grade 4 versus 8% in patients without bone metastases. Finally, at the start of sunitinib therapy, the mean number of metastatic sites was higher in patients with bone metastases than without (3.2 versus 2.3).
On the other hand, two observations suggest that this marked difference in outcome in patients with and without bone metastases under sunitinib therapy could also be explained in part by a therapeutic effect: the significant difference in RR in our series and the fact that in a study on 670 m-RCC patients receiving chemotherapy and immunotherapy, no difference in OS was recorded between patients with and without bone metastases (9.0 versus 10.3 months, P = 0.12) [7] . Thus, the presence of bone metastases could not only be a prognostic but also a predictive factor of response to sunitinib. We emphasize that the difference in RR is not due to difficult interpretation of responses in bone metastases. In fact, in all cases, except Table 2 ).
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the eight cases in which the bone was the only site of metastasis, the response was measured on target lesions outside the bone. Badalian et al. [16] observed on immunohistochemical analysis of 20 cases that VEGF-receptor-2 protein expression fell from 35% in the primary specimen to 10% in the bone metastasis, which could explain the lower impact of anti-VEGF-targeted therapy. We admit that due to the lack of more sensitive bone imaging like for instance full-body MRI, the impact of sunitinib on the bone metastases could not be precisely documented in our series. Nevertheless, our findings do not suggest that bone metastases are less controlled by sunitinib than metastases at other sites or that sunitinib is less effective in preventing new bone metastases than in preventing metastases at other sites. Our data are in line with those of Zolnierek et al. who studied the effects of sunitinib on preexisting bone metastases and the development of new bone metastases in 107 m-RCC patients. Progression of pre-existing bone metastases occurred in 1/4 patients (25%) and 8/28 patients (29%) on first-line and second-line sunitinib, respectively. In patients without bone metastases at the start of sunitinib therapy, bone metastases developed in 1/7 (14%) and 2/68 (3%) patients, respectively [17] .
An attractive hypothesis is that the aggressiveness of RCCs with bone metastases is due to the biology of the tumor or its microenvironment. Osteoclast activation due to the presence of malignant cells in the bone may liberate cytokines such as transforming growth factor-beta, bone morphogenic proteins, insulin-like growth factor, fibroblast growth factor, and platelet-derived growth factor, that can not only stimulate the local growth of malignant RCC cells but also circulate and stimulate growth at distance.
Our study has several limitations. It was a retrospective study with a limited number of patients per subgroup and no central radiologic review. It relied on CT scan and/or bone scintigraphy to assess bone metastases. Full-body MRI would be more reliable for the evaluation of bone metastases, more in particular for the evaluation of a partial response in the bone metastases. The impact of bone oriented therapies in our series is insufficiently documented and currently under evaluation.
In conclusion, the presence of bone metastases in m-ccRCC patients has a significant and clinically relevant negative impact on outcome on sunitinib. The presence of bone metastases should be taken into account in the elaboration of future predictive models and probably also in future clinical trials combining targeted and bone-oriented therapies in order to improve the outcome. 
